The Advisory Panel vote was an 11-2 AGAINST approval. The FDA will give
a CRL for sure. The FDA is looking for products that have a delivery
system that prevents abuse. They just had a special meeting on abuse of
sustained release products and the consensus was that not enough was
being done to prevent abuse. The decision to delay was made so they
could formulate a CRL letter that is consistent with the findings of the
meeting. If you are in this stock, you better get out before it goes
back to 75 cents. I shorted another 5000 shares at $1.95 today.
No comments:
Post a Comment